Abstract
The following table compares alcohol involvement in fatal motor-vehicle crashes by age group and blood alcohol concentration (BAC) levels for 1999 and 2000. A fatal crash is considered alcohol-related by the National Highway Traffic Safety Administration (NHTSA) if either a driver or nonoccupant (e.g., pedestrian) had a BAC of > or =0.01 g/dL in a police-reported traffic crash. Because BACs are not available for all persons in fatal crashes, NHTSA estimates the number of alcohol-related traffic fatalities on the basis of a discriminant analysis of information from all cases for which driver or nonoccupant BAC data are available.
Highlights
STAPHYLOCOCCUS AUREUS IS ONE OF THE most common causes of hospital- and community-acquired infections
The emergence of reduced vancomycin susceptibility in S. aureus increases the possibility that some strains will become fully resistant and that available antimicrobial agents will become ineffective for treating infections caused by such strains
The patient had a history of frequent hospitalizations for complications of hemodialysis-dependent, end-stage renal disease, and intravascular access, including two failed arteriovenous grafts, multiple central venous catheter-associated infections, and intermittent receipt of vancomycin therapy through June 1998
Summary
STAPHYLOCOCCUS AUREUS IS ONE OF THE most common causes of hospital- and community-acquired infections. Nosocomial methicillin-resistant S. aureus (MRSA) infections have become common, and cases of community-acquired. Aureus (VISA; vancomycin minimum inhibitory concentration [MIC] = 8-16 μg/mL) has been identified in Europe, Asia, and the United States.[3,4,5] The emergence of reduced vancomycin susceptibility in S. aureus increases the possibility that some strains will become fully resistant and that available antimicrobial agents will become ineffective for treating infections caused by such strains. Because few therapies are available to treat MRSA, the confirmed reports of VISA strains demonstrating reduced susceptibility to vancomycin, which has been the drug of last resort to treat MRSA, is of concern. (glycopeptide-intermediate S. aureus) have been used in the United States to describe S. aureus isolates with reduced susceptibility to vancomycin
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
